Research Square
Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2+ breast cancer
Publication
, Preprint
Noteware, L; Broadwater, G; Dalal, N; Alder, L; Herndon, J; Floyd, S; Swearingen, AV; Anders, C; Sammons, S
2022
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Noteware, L., Broadwater, G., Dalal, N., Alder, L., Herndon, J., Floyd, S., … Sammons, S. (2022). Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2+ breast cancer. Research Square. https://doi.org/10.21203/rs.3.rs-1921563/v1
Noteware, Laura, Gloria Broadwater, Nicole Dalal, Laura Alder, James Herndon, Scott Floyd, Amanda Van Swearingen, Carey Anders, and Sarah Sammons. “Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2+ breast cancer.” Research Square, 2022. https://doi.org/10.21203/rs.3.rs-1921563/v1.
Noteware L, Broadwater G, Dalal N, Alder L, Herndon J, Floyd S, et al. Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2+ breast cancer. Research Square. 2022.
Noteware, Laura, et al. “Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2+ breast cancer.” Research Square, 2022. Epmc, doi:10.21203/rs.3.rs-1921563/v1.
Noteware L, Broadwater G, Dalal N, Alder L, Herndon J, Floyd S, Swearingen AV, Anders C, Sammons S. Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2+ breast cancer. Research Square. 2022.